logo
The Most Consumed Veggie In The U.S. Is Full Of Pesticides, Per New Report

The Most Consumed Veggie In The U.S. Is Full Of Pesticides, Per New Report

Yahooa day ago

You've probably heard of the "Dirty Dozen" list. Each year, the Environmental Working Group (EWG) uses data from the USDA to pinpoint the produce with the most pesticides. Last year, strawberries have took the lead. But in the new Shopper's Guide to Pesticides in Produce, which was released on June 12, strawberries have been knocked out of their number one spot. And there are two newcomers to the list.
So what's the "dirtiest" fruit or veggie? In this year's list, spinach swapped places with strawberries for the number one spot. The leafy green was found to have "more pesticide residues by weight than any other type of produce," according to the site. 75% of non-organic samples contained permethrin, a neurotoxic insecticide banned in Europe.
New to the list are blackberries, which were tested by the USDA for the first time in 2023. And, potatoes, the most-consumed vegetable in the country, also made it to the Dirty Dozen. 90% of potato samples tested positive for chlorpropham, a chemical that prevents sprout growth—and a chemical that's banned in the European Union.
"EWG's Shopper's Guide is a tool to inform consumers and help them with their produce shopping choices, with the goal of everyone eating more fruits and vegetables,' says Alexis Temkin, PhD, EWG Vice President for Science, in the press release.
Other fruits and veggies that made it to the Dirty Dozen include dark leafy greens such as kale, collard greens, and mustard greens; grapes; peaches; cherries; nectarines; pears; and apples.
Produce with the lowest amounts of pesticide residue made it to the "Clean Fifteen." The top five include pineapples, sweet corn, avocados, papayas, and onions.
To determine the list, the EWG looks at pesticide residue from tests performed by the USDA. These tests included over 53,000 samples of 47 washed fruits and vegetables. This year's list used a new methodology to get a more accurate depiction of just how harmful dirty some fruits and veggies may be. In addition to the amount of pesticides, the study looked at toxicity, meaning how harmful the pesticides could be.
'Our research takes into account the potency of each chemical and can help shoppers reduce their overall pesticide burden," says Dayna de Montagnac, MPH, an associate scientist for the EWG.
You Might Also Like
Jennifer Garner Swears By This Retinol Eye Cream
These New Kicks Will Help You Smash Your Cross-Training Goals

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

2 Healthcare Stocks to Keep an Eye On and 1 to Ignore
2 Healthcare Stocks to Keep an Eye On and 1 to Ignore

Yahoo

time20 minutes ago

  • Yahoo

2 Healthcare Stocks to Keep an Eye On and 1 to Ignore

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 7.5%. This drop was discouraging since the S&P 500 held steady. The elite companies can churn out earnings growth under any circumstance, however, and our mission at StockStory is to help you find them. Taking that into account, here are two healthcare stocks we think can generate sustainable market-beating returns and one we're steering clear of. Market Cap: $4.48 billion Pioneering the shift from bulky, short-term heart monitors to sleek, wire-free patches, iRhythm Technologies (NASDAQ:IRTC) provides wearable cardiac monitoring devices and AI-powered analysis services that help physicians detect and diagnose heart rhythm disorders. Why Is IRTC Not Exciting? Issuance of new shares over the last five years caused its earnings per share to fall by 5.6% annually while its revenue grew Cash-burning history makes us doubt the long-term viability of its business model 124× net-debt-to-EBITDA ratio shows it's overleveraged and increases the probability of shareholder dilution if things turn unexpectedly iRhythm's stock price of $138.38 implies a valuation ratio of 78.4x forward EV-to-EBITDA. If you're considering IRTC for your portfolio, see our FREE research report to learn more. Market Cap: $3.51 billion Pioneering treatments for a devastating childhood muscle-wasting disease that primarily affects boys, Sarepta Therapeutics (NASDAQ:SRPT) develops and commercializes RNA-targeted therapies and gene therapies for rare genetic disorders, primarily Duchenne muscular dystrophy. Why Do We Love SRPT? Market share has increased this cycle as its 51.3% annual revenue growth over the last two years was exceptional Earnings per share grew by 41% annually over the last five years, massively outpacing its peers Cash-burning tendencies have improved over the last five years, showing it could become financially independent one day At $35.74 per share, Sarepta Therapeutics trades at 3.5x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it's free. Market Cap: $14.82 billion With a network spanning nine states and serving primarily urban and suburban communities, Tenet Healthcare (NYSE:THC) operates a nationwide network of hospitals, ambulatory surgery centers, and outpatient facilities providing acute care and specialty healthcare services. Why Do We Like THC? Share repurchases have amplified shareholder returns as its annual earnings per share growth of 30.7% exceeded its revenue gains over the last five years Market-beating returns on capital illustrate that management has a knack for investing in profitable ventures, and its returns are growing as it capitalizes on even better market opportunities Returns on capital are climbing as management makes more lucrative bets Tenet Healthcare is trading at $159.57 per share, or 13x forward P/E. Is now the right time to buy? Find out in our full research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy
Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy

Yahoo

time20 minutes ago

  • Yahoo

Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy

Sarepta Therapeutics has announced new outcomes from its open-label Phase Ib Study 9001-103, also referred to as the ENDEAVOR trial, of adeno-associated virus (AAV)-based gene transfer therapy Elevidys (delandistrogene moxeparvovec-rokl) to treat Duchenne muscular dystrophy (DMD). The multi-cohort ENDEAVOR study is aimed at evaluating the therapy's safety and protein expression in male subjects with DMD. Across seven cohorts, the trial enrolled 55 subjects and dosed participants who were aged between four and seven years old at the time of treatment, with varying degrees of mobility, and those younger than four years old. The primary endpoint of the trial is the change from baseline in Elevidys micro-dystrophin protein expression quantity at 12 weeks, as per western blot measurement, with secondary outcomes measuring dystrophin-positive fibres. In addition, the trial's exploratory endpoints evaluate the change in vector genome copies per nucleus, the North Star Ambulatory Assessment (NSAA), and timed functional tests. Inclusive of the first 12-week duration, subjects will undergo a follow-up period of a total of five years. In cohort 6, subjects aged two years old at the time of treatment showed a mean expression of 93.87% of normal dystrophin levels when treated with the therapy, with 79.9% dystrophin-positive fibres. These outcomes were observed in biopsies 12 weeks post-treatment. The safety seen in this cohort was found to be in line with the clinical and real-world applications of the therapy. Sarepta noted that the company has shared safety and expression from the trial's cohort 4, in which subjects were aged three at the time of treatment and showed a mean protein level of 99.64% in biopsies taken at the same post-treatment interval. More than 25 subjects below four years of age were treated in Sarepta's clinical trials. Sarepta Therapeutics research and development head and chief scientific officer Louise Rodino-Klapac said: 'The strength of the biomarker results that we are seeing in younger patients is extremely encouraging, and we have a meeting with the US Food and Drug Administration next month to discuss expanding the Elevidys label to include younger patients.' Last December, Sarepta completed enrolment and dosing for the Phase III EMERGENE trial of SRP-9003 (bidridistrogene xeboparvovec), targeting limb-girdle muscular dystrophy Type 2E/R4. "Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store